A major new lawsuit is challenging the notion that human genes can be patented just like the latest mousetrap built by a basement inventor. The case focuses on two genes, BRCA1 and BRCA2, that are linked to a higher risk of breast and ovarian cancer, and which were patented by the company Myriad Genetics more than 10 years ago. Now, the ACLU has organized a lawsuit backed by organizations representing more than 100,000 doctors and geneticists, and will argue that the information contained in each person’s DNA should not be private property.
The plantiffs also include individual cancer patients like Genae Girard, who was diagnosed with breast cancer, and took Myriad’s genetic test to see if her genes also put her at increased risk for ovarian cancer, which might require the removal of her ovaries. The test came back positive, so she wanted a second opinion from another test. But there can be no second opinion [The New York Times]. Since Myriad owns the patent to both the two genes and the test that looks for them, no other company can develop a competing test.
(more…)
The beating of the heart inside an embryo doesn’t just circulate blood through the developing creature, it also triggers the formation of blood stem cells, the cells that give rise to all other forms of blood cells, according to two new studies. The surprising findings show that the physical force of the heartbeat and blood flowing through the aorta cause embryonic stem cells to differentiate–although researchers don’t yet understand quite how this is accomplished.
The findings could eventually have practical applications for people with blood cancers and other diseases that are treated with transplants of bone marrow, the site of blood stem cell production. Scientists can make red and white blood cells easily in the laboratory, but bone marrow patients need blood stem cells to constantly replenish their blood supply. Producing these cells, also called hematopoietic stem cells, is much more difficult…. Only about a third of patients who require bone marrow transplants have matching donors. “Basically we cannot offer optimal therapy to two-thirds of patients” [Science News], says Leonard Zon, coauthor of one of the new studies. If researchers can learn how the body stimulates blood stem cell production, they may be able to duplicate the process in the lab, says Zon.
(more…)
In recent years, antioxidants have been touted as a secret to healthy living: The molecules bind to reactive oxygen compounds called “free radicals” that are known to damage the body’s tissues. The amount of oxidative damage increases with age, and according to one theory of aging it is a major cause of the body’s decline [The New York Times]. But a new study examined the effects of the antioxidant vitamins C and E when combined with an exercise regimen, and found a considerably more complicated story. The researchers found that free radicals may be beneficial in small doses, and may even help protect against diabetes. And mopping them up with antioxidants may do more harm than good [BBC News].
During a workout, the muscles metabolize glucose to create energy, but in the process some free radicals are released. The body has a natural defense mechanism to combat these free radicals, but many researchers had theorized that the body can’t catch all of the harmful compounds, which makes antioxidant supplements sound like a logical solution.
(more…)
Cardiologist and author John Sotos has a theory about why Abraham Lincoln was so tall, why he appeared to have lumps on his lips and even why he had gastrointestinal problems. The 16th president, he contends, had a rare genetic disorder — one that would likely have left him dead of cancer within a year had he not been assassinated [Time]. But for Sotos to prove his case, he needs a snip from a historical relic: a piece of the bloodstained pillowcase on which the dying Lincoln rested his head after he was shot at Ford’s Theater on April 14, 1865.
The piece of cloth is displayed under glass at the Grand Army of the Republic Civil War Museum and Library in Philadelphia. Sotos has asked the museum’s board for a sample of the pillowcase, which is stained with both blood and brain matter. But the board is fiercely debating whether to concede to his request. “This is the Shroud of Turin of Civil War history,” said Andy Waskie, a board member…. “We are guardians in trusteeship of this extraordinarily important artifact. On the basis of pure science, the testing is of interest. We have not eliminated it as an option . . . but we want more information” [The Philadelphia Inquirer].
(more…)
In a small step forward in the scientific effort to save the Tasmanian devil from the infectious disease that threatens the species with extinction, researchers have developed the first blood test for the ailment known as devil facial tumour disease (DFTD). Previously it has not been possible to determine whether a Tasmanian devil had DFTD until symptoms, such as facial lesions, appeared. However by early detection the diseased animals could be separated (and possibly culled) from healthy animals in the wild [Times Online]. The captive populations that are being kept as insurance against possible extinction could also be tested routinely.
Says researcher Robert Shellie: “We think it is quite a significant breakthrough. In a nutshell, what we have done is develop a blood test for DFTD. It’s a simple test and requires … only a drop of blood from an ear-prick. To be able to determine whether the disease is there, before you can see tumours on the faces of the devils, means that we can detect the disease at a much earlier stage” [The Australian].
(more…)
U.S. Attorney General Eric Holder announced yesterday that the federal government will not prosecute all sales of medical marijuana, marking another stark change in policy from the days of the Bush administration, which conducted frequent raids under a zero tolerance policy.
Medical marijuana distributors were targeted by federal officials under Bush even in states that had passed laws allowing use of the drug for medical purposes by cancer patients, those dealing with chronic pain or other serious ailments. Holder said the priority of the new administration is to go after egregious offenders operating in violation of both federal and state law, such as those being used as fronts for drug dealers [Los Angeles Times]. Under the new policy, medical marijuana dispensaries that abide by state laws will be left alone.
(more…)
A double-whammy method of screening for ovarian cancer, which is sometimes called the silent killer, seems to catch many cases in the early stages when the disease is more curable, researchers say. A massive study tested the impact of two types of screening: One is a blood test which measures the levels of a protein called CA125, which is often higher in women with ovarian cancer. The other is an ultrasound scan that looks for abnormalities in the ovaries [The Guardian]. When used in conjunction, the two tests showed great promise in catching cancer cases early on.
Ovarian cancer is one of the most lethal types of cancer. About 21,000 U.S. women are diagnosed each year and more than 15,000 die. The high death rate is due to the fact that the disease is often detected at a late stage of development, when chances for a cure are much lower [Los Angeles Times].
However, many of the women in the study had false positive results, especially those who received only an ultrasound test, leading some to unnecessarily have their ovaries removed. Lead researcher Ian Jacobs cautioned that “women thinking of having [an ultrasound screening] must understand and realize that there’s a possibility it will do more harm than good. We have reason to think it will save lives,” he added, “and then the question is, will it save enough lives to balance out the harm it does?”[The New York Times].
(more…)
A simple urine test is being developed that would revolutionize the treatment of prostate cancer by differentiating between the benign and aggressive forms of the disease.
While prostate cancer is one of the most commonly diagnosed cancers in men, the real challenge for treatment tends to lie in measuring the progress of the disease. A person can live a long time with benign prostate cancer, but the aggressive kind of tumor grows much more quickly and requires urgent treatment. The current method for distinguishing between the two can involve several rounds of testing, including an invasive and painful biopsy.
The urine test, which will not be ready for at least another three to five years, would be an easy and inexpensive way to determine which type of cancer is present, researchers report in Nature [subscription required]. Research for the test began when doctors found that men with an aggressive form of prostate cancer carry elevated levels of a particular molecule in their urine [The Guardian].
(more…)
The first clinical trial of a therapy based on human embryonic stem cells has received the green light from the FDA, marking a scientific and political milestone for embryonic stem (ES) cell research. The biotech company, Geron Corporation, received approval today for a study that would inject neural stem cells into patients suffering from spinal cord injuries. The study will be mainly a test for safety, but functional improvements, which have been observed in animals trials, may be possible. “For us, it marks the dawn of a new era in medical therapeutics. This approach is one that reaches beyond pills and scalpels to achieve a new level of healing,” Geron Chief Executive Dr. Thomas Okarma said [Reuters].
ES cells are taken from embryos a few days after fertilization and have the potential to differentiate into any type of cell in the body. The undifferentiated cells can’t be used directly, because they can form cancers called teratomas. But they can be used in the lab to generate potentially inexhaustible supplies of all other types of cell[s] that might be needed for repair. The type to be used in the trial are neural stem cells called oligodendrocyte progenitor cells. These support other neurons in the brain and nerves by supplying growth factors and by producing the myelin sheaths that protect neurons from damage [New Scientist]. The FDA will allow Geron to implant these neural stem cells directly into the spinal cords of eight to ten paraplegics. The trials are expected to begin this summer, and may be carried out in multiple medical centers. The patients have not yet been recruited because the injections must take place within two weeks of the spinal cord injury, before scar tissue forms.
(more…)
Researchers had high hopes for Cedric the Tasmanian devil: They believed he was the first member of the species to be immune to the deadly facial cancer that is rapidly devastating devil populations. Now, in a major setback, Cedric has grown two small tumors and researchers are back to square one. Many experts believe that the infectious cancer, called devil facial tumor disease, could drive the species to extinction within 20 years if it goes unchecked.
Cedric was captured in western Tasmania last year, along with his half-brother, Clinky. Both were injected with dead tumours by scientists. Clinky produced no antibodies, but Cedric did, and appeared to have built-in defences against the illness [BBC News]. However, the next step yielded worse results. Researchers injected two live strains of the disease into Cedric’s cheek in an attempt to prove his immunity, but two small tumors grew at the injection sites. The tumors were surgically removed last week, and while Cedric is expected to make a full recovery, his love life has been put on hold by the researchers. They were trying to get him to mate so he would pass on his genes. Now they’re unsure if Cedric is naturally immune to the disease [ABC News].
(more…)
Pharmaceutical giant Wyeth is under scrutiny for its practice of paying ghostwriters to draft scientific journal articles favorable to its products and publishing them under the names of academic researchers. Some of the ghostwritten reports involve Wyeth’s hormone replacement therapy, Prempo, and deny the results of a federal study that linked the drug to an increased risk for breast cancer. The inquiries come as part of the Senate Finance Committee’s examination of “medical ghostwriting,” part of a broader probe into the influence of drug companies on the health-care industry [Wall Street Journal].
The investigation is being spearheaded by Senator Charles E. Grassley of Iowa, who last week sent a letter to Wyeth’s chairman requesting documentation of the company’s ghostwriting and publishing procedures. The letter [pdf] said Wyeth’s publications resembled “subtle advertisements rather than publications of independent research” and that “any attempt to manipulate the scientific literature, that can in turn mislead doctors to prescribe drugs that may not work and/or cause harm to their patients, is very troubling.” In response, a Wyeth spokesman accused Mr. Grassley of recycling old arguments and insisted that “The authors of the articles in question, none of whom were paid, exercised substantive editorial control over the content of the articles and had the final say, in all respects, over the content” [New York Times].
(more…)
Cancer will be the world’s leading killer by 2010, edging out heart disease for the top spot, according to the latest report by the World Health Organization (WHO). Though cancer rates in the United States have just recently begun to decrease, elsewhere in the world cancer is on a steady rise. Experts cite tobacco, increasingly Western lifestyles, and inadequate medical care as the factors contributing to the cancer epidemic in developing countries. “In the U.S., we pay a lot of attention to cancer trends, and the trend has been encouraging,” says Dr. Richard Schilsky… “But we have forgotten that there is a big wide world out there. Cancer is a global problem” [TIME].
According to the WHO report, 12 million new cases of cancer will be diagnosed this year and 7 million will die from the disease. The group forecast a 1 percent increase globally each year, with emerging economies such as China, Russia and India being hit the hardest [CNN]. The report also projects a 38 percent population increase in less developed countries by 2030. Taken together, that means by 2030 an estimated 20 to 26 million new cases of cancer will be diagnosed annually and 13 to 17 million deaths will be cancer-related.
(more…)
A promising target for next-generation cancer therapies might not be a target after all, according to a new study in Nature [subscription required]. The work calls into question the “cancer stem cell theory,” which claims that a rare class of cells, cancer stem cells, are responsible for initiating and spreading cancer tumors. But by tweaking previous experimental procedures, researchers working with human melanoma cells in mice now report that cancer stem cells are much more prevalent that previously thought. “We’re not trying to claim there is no merit to the field, but we think that the frequency of cancer stem cells will be much higher,” said [co-author] Sean Morrison… . “And there will be some cancers like melanoma where lots of cells will be tumorigenic and it won’t be possible to treat those cancers by treating a small subset of cells” [Wired Science].
Cancer stem cells—so-called because they share genetic similarities with standard stem cells—were first identified in 1994 and since then have been reported in cancers of the brain, breast, colon, and pancreas. They provided a well-defined target for cancer drugs since they were thought to number only a few in a million. Like evil relatives of standard organ-forming stem cells, cancer stem cells build tumors. It’s an appealing idea because it provides a new, well defined target for treatment [Wired News]. However, not everyone in the field was smitten with the new theory.
(more…)
One in five breast cancer tumors may regress without treatment, a new study suggests. Researchers screening women who had a history of regular mammograms and those who did not report that those in the first group were diagnosed with 22 percent more breast cancers, implying that such a percentage of cancers would have eventually gone away on their own. The study opens up a controversial debate on whether early and aggressive treatment of breast cancer is always the best procedure. But many experts are wary of the new findings, saying the conclusions were incorrectly drawn and fearing they will discourage women from getting mammograms. “The idea that somehow these cancers go away entirely is, I would say, an intriguing hypothesis, but one we don’t have a lot of evidence to support,” [Reuters] said Dr. Eric Winer.
Researchers in Norway followed two groups of women, each numbering more than 100,000, for six years. The first group, monitored from 1992 to 1997, did not receive mammograms until the end of the study. (Mammograms were not common in Norway until 1996.) The second group, monitored from 1996 to 2001, received mammograms every two years. For every 100,000 women who were screened regularly, 1,909 were diagnosed with invasive breast cancer over six years, compared with 1,564 women who did not have regular screening [New York Times]—a difference of 22 percent. The researchers attribute this difference to the number of undetected tumors in the first group that vanished on their own during those six years.
(more…)
Dosing menopausal women with testosterone may be the key to helping those with low libidos get back in the mood, according to a new study. Proctor & Gamble Pharmaceuticals has published the results of a new trial of their testosterone patch, called Intrinsa, and say the results are encouraging for frustrated older women seeking a “Viagra for women.” However, nagging safety concerns are likely to keep the drug off the market in the United States for some time to come (although the drug is already on sale in Europe): During the new study, four of the test subjects using the patch developed breast cancer.
The 52-week study included 814 women with sexual desire disorder, characterized by troublesome low sexual desire or function…. The women were asked to keep sexual encounter diaries, and researchers used other established measures to assess sexual response during the six-month evaluation phase of the study. They found that compared to placebo users, the women who used the 300 microgram patch reported significant improvements in sexual functioning, including desire, arousal, orgasm, and pleasure [WebMD].
(more…)
